On 2016-01-23, the FDA granted a supplemental approval for Opdivo (nivolumab), specifically addressing its efficacy. This action by the FDA indicates an update to the drug's approved profile, sponsored by Bristol Myers Squibb.
Background
Nivolumab, known commercially as Opdivo, is a prescription medication developed and marketed by Bristol Myers Squibb. As an existing approved drug, Opdivo has previously received FDA approvals for various indications. Supplemental applications, such as this one, are common regulatory mechanisms used to update or expand a drug's approved label based on new clinical data or manufacturing information. This particular supplemental approval focuses on the efficacy of the drug, indicating a review of additional data supporting its therapeutic benefits.
What this means
This supplemental FDA approval for Opdivo (nivolumab), specifically concerning its efficacy, signifies that the agency has reviewed and accepted additional data related to the drug's effectiveness. While the precise details of the updated efficacy claims, such as a new indication, an expanded patient population, or a revised dosing regimen, are not specified in this regulatory record, such approvals are crucial for refining the drug's approved label. For healthcare professionals, this means there is new, FDA-validated information that may influence prescribing decisions or patient management strategies. Researchers may find this update relevant for understanding the evolving clinical profile of nivolumab and guiding future studies. Patient advocates can use this information to stay informed about the latest regulatory status of an important therapeutic option. Ultimately, this approval reinforces the drug's therapeutic value and provides updated guidance on its appropriate use, contributing to more informed clinical practice.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Opdivo (nivolumab), identified as BLA 125554 S-7, was recorded on 2016-01-23 on accessdata.fda.gov.